'Fun­da­men­tal­ly dif­fer­en­t' from Por­to­la, Dutch biotech lands €32M to steer an­ti-an­ti­co­ag­u­lant through the clin­ic

Por­to­la may not have had much suc­cess prov­ing the com­mer­cial val­ue of an an­ti-an­ti­co­ag­u­lant, but that’s not stop­ping Eu­ro­pean in­vestors from pour­ing $36.2 mil­lion (€32 mil­lion) in­to what they see as a su­pe­ri­or ap­proach put forth by a Dutch biotech.

Var­mX’s blood thin­ner re­ver­sal agent stems from re­search done by founder and CSO Pieter Re­its­ma at Lei­den Uni­ver­si­ty Med­ical Cen­ter. A mod­i­fied re­com­bi­nant form of fac­tor X, VMX-C001 “has an in­ser­tion of 16 amino acids that re­places a stretch of 7 amino acids in the so-called ser­ine pro­tease do­main” com­pared to the na­tive co­ag­u­la­tion fac­tor, CEO Alexan­der Vos told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER